Migraine Prophylaxis in Adults Without Contraindications

First‑Line Oral Preventive Options

Propranolol is recommended as a first‑line preventive medication for adults without asthma, severe bradycardia, or uncontrolled depression, with strong evidence supporting its efficacy; typical dosing ranges from 80 mg to 240 mg daily. 1
Topiramate is indicated for both episodic and chronic migraine prevention, but carries a weak recommendation because of potential cognitive side effects; start at 25 mg and titrate to 50–200 mg daily. 1
Valproate (divalproex sodium or sodium valproate) is advised for episodic migraine prevention with a weak recommendation; usual dosing is 500–1500 mg daily. 1

CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab) receive a strong recommendation for both episodic and chronic migraine prevention when first‑line agents fail or are not tolerated. 1
Atogepant, an oral CGRP receptor antagonist, has a weak recommendation for episodic migraine prevention. 1
Eptinezumab, an intravenous CGRP monoclonal antibody, is given a weak recommendation despite requiring infusion administration. 1

Candesartan or telmisartan (angiotensin‑II receptor blockers) are strongly recommended for episodic migraine prevention, particularly useful in patients with co‑existing hypertension. 1
Lisinopril (ACE inhibitor) carries a weak recommendation for episodic migraine prevention. 1

OnabotulinumtoxinA injections receive a weak recommendation for chronic migraine prevention (≥15 headache days per month). 1
OnabotulinumtoxinA is not recommended for episodic migraine (weak recommendation against use). 1

Gabapentin has a weak recommendation against its use for episodic migraine prevention. 1
Fluoxetine and venlafaxine lack sufficient evidence for migraine prevention according to VA/DoD guidelines, resulting in a recommendation against their use. 1
Rimegepant does not have adequate evidence to support its use for migraine prevention. 1

Memantine is assigned a weak recommendation as an adjunctive oral agent for episodic migraine when other options have failed. 1

Patients with headache frequency ≥7 days per month should be monitored for medication‑overuse headache, especially if acute analgesics are used frequently. 1

All statements are derived from the cited source and reflect the strength of evidence and guideline recommendations where specified.

The 2025 American College of Physicians (ACP) guidelines do not recommend B‑vitamins as first‑line therapy for migraine prevention. [2][3]
First‑line migraine prophylaxis per the 2025 ACP guidelines includes beta‑blockers (metoprolol, propranolol), valproate, venlafaxine, or amitriptyline. 2
Second‑line options recommended by the 2025 ACP guidelines are CGRP antagonists (atogepant, rimegepant) or CGRP monoclonal antibodies (eptinezumab, erenumab, fremanezumab, galcanezumab). 2
If first‑line agents fail, the 2025 ACP guidelines suggest angiotensin‑II receptor blockers (candesartan, telmisartan), ACE inhibitors (lisinopril), or SSRIs (fluoxetine) as subsequent choices. 3

B‑vitamins are absent from ACP evidence‑based recommendations, reflecting insufficient comparative‑effectiveness data to support routine use for migraine prophylaxis. [2][3]
The omission of B‑vitamins from major 2025 guidelines is due to a lack of head‑to‑head comparative effectiveness trials against established preventive medications. [2][3]
Current evidence is deemed insufficient to elevate B‑vitamins to first‑line status over proven pharmacologic agents. [2][3]

B‑vitamins should not replace guideline‑recommended first‑line treatments in patients with severe, disabling migraine who require robust prophylaxis. [2][4]
When B‑vitamins are trialed as adjuncts, response should be monitored over a 2–3‑month period, consistent with standard migraine prevention trial durations. 3

Topiramate is preferred for patients with obesity because it is associated with weight loss, making it a favorable first‑line oral preventive option in this subgroup. 5
Amitriptyline may be selected for patients with depression or sleep disturbances, although it is considered a second‑line agent due to its higher adverse‑event burden. 5

CGRP monoclonal antibodies are often subject to insurance restrictions that require prior failures of other preventives, despite guideline statements supporting their use as first‑line therapy when cost and access permit. 5
Patients should be educated about the risk of medication‑overuse headache when they use acute analgesics frequently (≥ 7 days per month), to promote appropriate acute‑medication use. 5

For chronic migraine (≥ 15 headache days per month), topiramate, onabotulinumtoxinA, and CGRP monoclonal antibodies are recommended as first‑line preventive treatments. 5
Patients with chronic migraine should be referred to a headache specialist for comprehensive management. 5
Traditional beta‑blockers, angiotensin‑II receptor blockers (candesartan/telmisartan), and amitriptyline lack robust randomized controlled trial data for chronic migraine, indicating limited evidence for their use in this population. 5